Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Insider Sells $125,928.31 in Stock

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) insider Terrie Curran sold 19,109 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $6.59, for a total value of $125,928.31. Following the sale, the insider now directly owns 360,465 shares of the company’s stock, valued at $2,375,464.35. This represents a 5.03 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Phathom Pharmaceuticals Price Performance

Shares of NASDAQ PHAT traded up $0.18 during mid-day trading on Thursday, reaching $7.17. The company’s stock had a trading volume of 649,135 shares, compared to its average volume of 943,045. The stock has a fifty day moving average of $8.08 and a two-hundred day moving average of $12.53. Phathom Pharmaceuticals, Inc. has a 52 week low of $6.07 and a 52 week high of $19.71. The firm has a market capitalization of $490.28 million, a PE ratio of -1.26 and a beta of 0.56.

Phathom Pharmaceuticals (NASDAQ:PHAT) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($1.32) EPS for the quarter, beating analysts’ consensus estimates of ($1.57) by $0.25. The firm had revenue of $16.35 million for the quarter, compared to the consensus estimate of $12.54 million. During the same period in the previous year, the company posted ($0.76) earnings per share. Analysts anticipate that Phathom Pharmaceuticals, Inc. will post -4.74 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have issued reports on PHAT shares. Needham & Company LLC reissued a “buy” rating and set a $28.00 price target on shares of Phathom Pharmaceuticals in a report on Friday, January 10th. HC Wainwright reissued a “buy” rating and set a $28.00 price target on shares of Phathom Pharmaceuticals in a report on Thursday, December 12th.

Institutional Investors Weigh In On Phathom Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Huntington National Bank raised its holdings in shares of Phathom Pharmaceuticals by 62.2% in the third quarter. Huntington National Bank now owns 1,471 shares of the company’s stock worth $27,000 after buying an additional 564 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Phathom Pharmaceuticals by 41.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,470 shares of the company’s stock worth $43,000 after buying an additional 722 shares during the period. US Bancorp DE raised its holdings in shares of Phathom Pharmaceuticals by 28.6% in the third quarter. US Bancorp DE now owns 5,248 shares of the company’s stock worth $95,000 after buying an additional 1,166 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of Phathom Pharmaceuticals by 10.6% in the second quarter. The Manufacturers Life Insurance Company now owns 13,941 shares of the company’s stock worth $144,000 after buying an additional 1,339 shares during the period. Finally, Quest Partners LLC purchased a new stake in shares of Phathom Pharmaceuticals in the third quarter worth approximately $197,000. 99.01% of the stock is currently owned by hedge funds and other institutional investors.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.